Medication info
Clovertin Tablets 20mg (Rosuvastatin Calcium)

Clovertin Tablets 20mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Genupharma Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets/Alu-Alu packaging x 2), 30 tablets/bottle
Approval status
Active

MFDS item code 201506639 · Approved 2015.09.18 · Insurance code 698002950

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Genupharma Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medicine is used in cases of primary hypercholesterolemia and mixed dyslipidemia where diet and exercise alone are not sufficient. It is also used as an adjunct therapy for homozygous familial hypercholesterolemia, reducing total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia and delaying the progression of atherosclerosis. It is utilized as an adjunct to dietary therapy in children aged 10 to 17 years with heterozygous familial hypercholesterolemia. In addition, it aids in dietary management for patients with primary dysbetalipoproteinemia. In middle-aged and older adults with high-sensitivity C-reactive protein levels, it reduces the risk of cardiovascular disease and contributes to lowering the risk of stroke, myocardial infarction, and vascular interventions. This medication effectively improves cholesterol and cardiovascular disease risks.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, those who are allergic to this medication, have severe liver impairment, have muscle disorders, or are pregnant or breastfeeding should not take it. Caution should be exercised when administering this medication to patients with reduced liver function or those who consume large amounts of alcohol. Regular liver function tests should be performed before and during treatment. Symptoms such as muscle pain or weakness may occur, so if these symptoms arise, the physician should be informed immediately, and the medication should be discontinued if necessary. The risk of side effects may increase when this medication is taken with other drugs, so if other medications are being taken, it is essential to inform the doctor or pharmacist. This medication may increase blood glucose levels, so individuals at risk for diabetes should pay closer attention to blood sugar management. Women who might become pregnant should use appropriate contraception to avoid pregnancy, and if pregnancy occurs, this medication should be discontinued immediately. Regular monitoring of liver function, muscle condition, and renal function should be done during treatment, and if any unusual symptoms develop, medical consultation should be sought immediately. In case of overdose, there is no specific antidote, so the patient should go to the hospital for symptomatic treatment. This medication can rarely cause severe skin reactions or pulmonary diseases, so if there are severe rashes or difficulty breathing, it should be discontinued immediately, and the hospital should be visited. Caution is needed while driving or operating machinery as dizziness may occur.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruptions, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained between 1 to 30 degrees Celsius. Proper storage helps to maintain the drug's effectiveness for a longer duration.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets/Alu-Alu packaging x 2), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.